Trader consensus on Polymarket reflects an 88.5% implied probability for no new pandemic in 2026, driven by the absence of any novel pathogen achieving sustained human-to-human transmission across multiple WHO regions, per the organization's pandemic criteria. Official surveillance from WHO and CDC reports no alarming clusters as of mid-April: Ethiopia's Marburg outbreak ended in January, H5N1 avian influenza cases remain sporadic without efficient person-to-person spread (e.g., 71 U.S. cases since 2024, mostly mild), and regional threats like measles or chikungunya fall short of global epidemic thresholds. WHO's April 7 R&D roadmaps underscore proactive preparedness amid ongoing monitoring, with epidemiological baselines stable post-COVID enhancements. Unforeseen viral adaptations could shift odds, but current data supports this positioning ahead of quarterly updates.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$227,182 Vol.
$227,182 Vol.
$227,182 Vol.
$227,182 Vol.
The resolution source will be official announcements from the World Health Organization.
Market Opened: Dec 1, 2025, 4:37 PM ET
Resolver
0x65070BE91...The resolution source will be official announcements from the World Health Organization.
Resolver
0x65070BE91...Trader consensus on Polymarket reflects an 88.5% implied probability for no new pandemic in 2026, driven by the absence of any novel pathogen achieving sustained human-to-human transmission across multiple WHO regions, per the organization's pandemic criteria. Official surveillance from WHO and CDC reports no alarming clusters as of mid-April: Ethiopia's Marburg outbreak ended in January, H5N1 avian influenza cases remain sporadic without efficient person-to-person spread (e.g., 71 U.S. cases since 2024, mostly mild), and regional threats like measles or chikungunya fall short of global epidemic thresholds. WHO's April 7 R&D roadmaps underscore proactive preparedness amid ongoing monitoring, with epidemiological baselines stable post-COVID enhancements. Unforeseen viral adaptations could shift odds, but current data supports this positioning ahead of quarterly updates.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions